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ABSTRACT
Objective To identify recent trends in, and factors
associated with, resistance to antituberculosis drugs in
England, Wales, and Northern Ireland.
Design Cohort of tuberculosis cases reported to the
enhanced tuberculosis surveillance system matched to
dataondrugsusceptibility andnational strain typingdata.
Setting England,Wales, andNorthern Ireland 1998-2005.
Main outcome measures Unadjusted and adjusted odds
ratios for drug resistance and associated factors.
Proportion of multidrug resistant tuberculosis cases
clustered.
Results 28620 culture confirmed caseswere available for
analysis. The proportion of cases resistant to isoniazid
increased from5%to7%.Rifampicin resistance increased
from 1.0% to 1.2% andmultidrug resistance from 0.8% to
0.9%. Ethambutol and pyrazinamide resistance remained
stable at around 0.4%and0.6%, respectively. Regression
analyses showed a significant increase in isoniazid
resistance outside London (odds ratio 1.04, 95%
confidence interval 1.01 to 1.07, a year, associated with
changes in age (0.98, 0.98 to 0.99, a year), place of birth
(1.49, 1.16 to 1.92), and ethnicity (P<0.05). In London, the
rise (1.05, 1.02 to 1.08, a year) was related mainly to an
ongoing outbreak. Increases in rifampicin resistance
(1.06, 1.01 to 1.11, a year) and multidrug resistance
(1.06, 1.00 to 1.12, a year) were small. A fifth of patients
with multidrug resistant tuberculosis in 2004-5 had
indistinguishable strain types, and one case was
identified as extensively drug resistant.
Conclusions The rise in isoniazid resistance reflects
increasing numbers of patients from sub-Saharan Africa
and the Indian subcontinent, who might have acquired
resistance abroad, and inadequate control of
transmission in London. The observed increases highlight
the need for early case detection, rapid testing of
susceptibility to drugs, and improved treatment
completion.
INTRODUCTION
Since 1987 the incidence of tuberculosis in England,
Wales, and Northern Ireland has increased signifi-
cantly, with more than 8000 cases reported in 2006.1
Resistance to antituberculosis drugs is increasing
globally,2 and transmission of drug resistant tubercu-
losis has been shown among marginalised groups in
urban areas, such as London.3 These factors may
contribute to the prevalence and transmission of drug
resistant strains in theUnitedKingdomand potentially
hamper tuberculosis control.
Data on drug susceptibility have been routinely
collected in the UK since 1993. Drug resistance,
including multidrug resistance, remained stable from
1993 to 1999.4 5 We examined recent trends in
resistance to antituberculosis drugs among cases
reported in England, Wales, and Northern Ireland
from 1998 to 2005 and investigated factors associated
with resistance.
METHODS
Data on drug susceptibility for initial isolates were
available from the UK Mycobacterial Surveillance
Network (MycobNet),whichcollates information from
all UK mycobacterial reference laboratories on first
isolates identified asMycobacterium tuberculosis complex
within a 12 month period. Drug susceptibility testing
was performed with the resistance ratio or the
proportionmethod.6Reports resulting fromlaboratory
cross contamination are removed from the database.
To improve the demographic and clinical information
available, we matched MycobNet records to the
national enhanced tuberculosis surveillance
database.1 This database provides information on
tuberculosis cases reported in England and Wales
since 1998 and inNorthern Ireland since 2000but does
not include data from Scotland. Detailed information
on data collection methods since 1999, the 1998
national tuberculosis survey, and MycobNet, has
been reported previously.4 7-9
Tuberculosis cases were either confirmed by culture
to be caused by M tuberculosis complex or met the
following criteria: a clinician’s judgment that the
patient’s clinical or radiological signs are compatible
with tuberculosis and clinician’s decision to treat the
patient with a full course of antituberculosis treatment.
In theUK first line antituberculosis drugs are isoniazid,
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rifampicin, pyrazinamide, and ethambutol (or more
rarely streptomycin).10 Multidrug resistant tuberculo-
sis is defined as resistance to at least isoniazid and
rifampicin and extensively drug resistant tuberculosis
as resistance to at least rifampicin, isoniazid, a
fluoroquinolone, and one of three injectable second
line drugs (amikacin, kanamycin, capreomycin).11 All
analyseswereperformedamongMtuberculosiscomplex
isolates that werematched to the surveillance database
and had results on drug susceptibility for at least
isoniazid and rifampicin. As most M bovis isolates are
resistant to pyrazinamide, we excluded these from
analyses of pyrazinamide resistance.
We inspected trends in resistance to first line drugs
from1998 to 2005 and tested significanceof odds ratios
for a linear trend using univariable and multivariable
logistic regression modelling (SPSS version 14.0).
Multivariable models adjusted for age, sex, place of
birth (born in the UK or elsewhere), ethnic group
(white, black Caribbean, black African, black other,
Indian/Pakistani/Bangladeshi, Chinese, other includ-
ing mixed), region (London versus outside London),
and previous diagnosis, factors previously reported to
be associated with resistance.12-14We also included site
of disease (pulmonarywith orwithout extrapulmonary
versus extrapulmonary disease only) to explore
potential effects on transmission. As we were aware
of an outbreak of isoniazidmonoresistance in London,
with limited evidence of transmission outside London,
we stratified analyses for isoniazid resistance by
region.2 Interactions between previous diagnosis,
region, place of birth, and ethnic group were investi-
gated and multiple interactions of P<0.01 supported
stratification of the analyses for isoniazid resistance by
region of reporting.
To identify trends in second line drug resistance and
cases of extensively drug resistant tuberculosis, we
undertook a review of second line drugs for cases of
multidrug resistant tuberculosis for 2002-5. Strain
typing information based on 15 loci variable number
tandem repeats (MIRU-VNTR), performed as
described previously,15 16 was collated for multidrug
resistant cases reported in 2004-5, entered into
BioNumerics version 4.5 (Applied Maths, St-Martin-
Latem, Belgium),17 and analysed by use of the
categorical coefficient to assess recent transmission.
The proportion clustered was calculated with the n−1
method.18
RESULTS
From1998 to2005, 34 555 initial isolateswere identified
asMtuberculosis complexand53602casesof tuberculosis
were reported to the national surveillance system.
Matching of the two databases resulted in 28 620 culture
confirmed cases (82.8% of initial isolates; 53.4% of case
reports). Results of drug susceptibility testing for
isoniazid and rifampicin were available for 28 485
cases (99.5% of culture confirmed cases), and we
included these in our analyses.
Table 1 shows the characteristics of culture confirmed
cases with results on drug susceptibility compared with
non-culture confirmed cases. The median age of these
patients was 35 (interquartile range 26-54); 57% were
male (16 164); 69% (17 522) were born outside the UK,
24% of whom entered less than two years before
diagnosis; 8% (1889) had had a previous diagnosis of
tuberculosis; and 42% (11 851) of cases were reported
from London. Similar proportions were seen among
non-culture confirmed cases. Patients with culture
confirmed tuberculosis more often had pulmonary
disease (67% v 50% of all other cases) and more often
had positive results on sputum smear tests (61% v 26%).
The proportion of patients who were culture confirmed
remained stable at about 55% over the study period.
Trends in first line drug resistance
Figure 1 and table 2 show the proportion of cases
resistant to each first line drug, any first line drug, and
those with multidrug resistant tuberculosis by year.
From 1998 to 2005 the percentage of cases resistant to
any first line drug increased from 5.6% to 7.5% (with a
peak of 7.9% in 2004). Isoniazid resistance increased
from 5.0% to 7.2% in 2003 and remained stable
thereafter. Multidrug resistance and rifampicin resis-
tance increased from 0.8% to 0.9% and 1.0% to 1.2%,
respectively. Resistance to pyrazinamide and
Table 1 | Characteristics of patientswith culture confirmed tuberculosiswith results on drug
susceptibilityforisoniazidandrifampicinandallotherreportedtuberculosispatients.Figuresare
numbers* (percentages) of patients, unless stated otherwise
Culture confirmed cases (tested
for isoniazid and rifampicin)
Non-culture confirmed cases (or
not tested for isoniazid and
rifampicin)
All cases 28 485 25 117
Median (IQR) age (years) 35 (26-54) 38 (25-59)
Male 16 164 (56.8) 13 239 (52.8)
Born in UK 8035 (31.4) 8318 (37.6)
Born outside UK:
Total 17 522 (68.6) 13 811 (62.4)
Median (IQR) timesinceentry toUK
(years)
4 (2-13) 5 (2-17)
Ethnic group:
White 7541 (27.7) 7235 (30.3)
Black Caribbean 770 (2.8) 560 (2.3)
Black African 5967 (21.9) 4257 (17.8)
Black other 241 (0.9) 159 (0.7)
Indian, Pakistani, Bangladeshi 9963 (36.6) 9405 (39.3)
Chinese 448 (1.6) 309 (1.3)
Other 2327 (8.5) 1986 (8.3)
Reported in London 11 851 (41.6) 10 702 (42.6)
Pulmonary disease† 18 997 (67.0) 12 437 (50.4)
Previous diagnosis 1889 (8.3) 2069 (10.3)
Species:
M tuberculosis 27884 (99.4) —
M bovis 123 (0.4) —
M africanum 33 (0.1) —
Positive resultonsputummicroscopy 9909 (60.6) 2340 (26.3)
IQR=interquartile range.
*Numbers do not always add up to total because of missing data.
†Pulmonary with or without extrapulmonary disease.
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ethambutol was low and no increases were noted. No
further analysis was undertaken for these two drugs.
There was a significant linear trend of increasing
isoniazid resistance apparent in univariable analyses,
inside and outside London (1.05, 95% confidence
interval 1.02 to 1.08, and 1.04, 1.01 to 1.07, respec-
tively, table 3). Levels of multidrug resistance and
rifampicin resistance also showed a significant linear
trend over the period (1.06, 1.00 to 1.12, and 1.06, 1.01
to 1.11, respectively, table 4).
Factors associated with trend
On multivariable analysis, the increase in isoniazid
resistance outside London and the increases in
rifampicin resistance and multidrug resistance were
no longer significant. In London, the rise in isoniazid
resistance remained significant (1.04, 1.0 to 1.1).
Specifically, adjustment for ethnicity, place of birth,
or age each resulted in the rise in isoniazid resistance
outside London no longer being significant (P for
year=0.19, 0.15, and 0.11, respectively). For multidrug
resistance adjustment for previous diagnosis also had
this effect (P for year=0.14). Figure 2 shows the levels of
drug resistance by year after adjustment for these four
variables and shows that nationally the increase in
isoniazid resistance remained significant, while the
increases in rifampicin resistance and multidrug
resistance were no longer significant.
In all models, younger age was significantly asso-
ciated with resistance, while sex was not (tables 3 and
4). Patients born outside the UK had a higher risk of
drug resistance, including isoniazid resistance outside
London, but a lower risk of isoniazid resistance in
London. Compared with the white ethnic group, the
risk of isoniazid resistance was significantly higher in
black Caribbean patients in London (2.9, 2.1 to 4.1).
Outside London, and for rifampicin resistance and
multidrug resistance, the risk was higher in the black
African, black other, Indian-Pakistani-Bangladeshi,
and the Chinese ethnic groups (tables 3 and 4).
Patients with a previous diagnosis of tuberculosis
were significantly more likely to be resistant in all
models (tables 3 and 4). Thosewith pulmonary disease
were significantlymore likely tobe rifampicin resistant.
Resistance to second and third line drugs among cases of
multidrug resistant tuberculosis
Information on susceptibility to second and third line
drugswas available for 99%ofmultidrug resistant cases
reported in 2002-5. Because of the small numbers, it is
difficult to assess trends in second line drug resistance.
Resistance to second and third line drugs was low, with
the exception of resistance to para-aminosalicylic acid
(14%) and ethionamide (9%) (data available from
authors). In 2003 one patient with no history of
tuberculosis was found to have extensively drug
resistant tuberculosis.
Molecular clusters of multidrug resistant tuberculosis
Wehad informationon strain typing for 82% (66/81) of
multidrug resistant cases reported in 2004-5. Six
clusters of indistinguishable MIRU-VNTR patterns
were identified. The proportion clustered, calculated
with the n−1 method, was 19.7%. A cluster of six
patients (Beijing strain), five of whom lived in the same
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Fig 1 | Proportion of tuberculosis cases confirmed by culture
(with test results for both isoniazid and rifampicin) resistant to
first line drugs, multidrug resistant, and resistant to any first
line drug by year, and significance of trend over time
Table 2 | Number (percentage)ofcultureconfirmedtuberculosiscaseswithfirst linedrugresistance,multidrug resistance,andany
first line drug resistance by year, 1998-2005
Year Isoniazid Rifampicin Pyrazinamide* Ethambutol Multidrug
Any first line
drug All cases†
1998 154 (5.0) 31 (1.0) 19 (0.6) 14 (0.5) 23 (0.8) 170 (5.6) 3058
1999 172 (5.8) 20 (0.7) 17 (0.6) 13 (0.4) 17 (0.6) 189 (6.3) 2980
2000 176 (6.0) 38 (1.3) 21 (0.7) 11 (0.4) 27 (0.9) 198 (6.7) 2942
2001 217 (6.5) 36 (1.1) 17 (0.5) 13 (0.4) 24 (0.7) 238 (7.2) 3317
2002 267 (7.1) 41 (1.1) 27 (0.7) 18 (0.5) 31 (0.8) 291 (7.7) 3776
2003 276 (7.2) 68 (1.8) 20 (0.5) 19 (0.5) 49 (1.3) 303 (7.9) 3823
2004 295 (7.2) 57 (1.4) 27 (0.7) 17 (0.4) 43 (1.0) 324 (7.9) 4114
2005 310 (6.9) 54 (1.2) 13 (0.3) 16 (0.4) 39 (0.9) 336 (7.5) 4475
All years 1867 (6.6) 345 (1.2) 161 (0.6) 121 (0.4) 253 (0.9) 2049 (7.2) 28485
*Excludes cases of M bovis.
†All culture confirmed cases with susceptibility testing results for at least isoniazid and rifampicin.
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area/city, was known to be an outbreak. All were from
ethnic minority groups but included people born
within and outside the UK. Four MDR-TB cases
(LAM10 CAM) were part of the outbreak of isoniazid
mono-resistance originating in north London2 but
might have acquired rifampicin resistance additionally
as a result of poor compliance.19 Another cluster of
three or four cases (CAS1 Delhi) was less likely to be
caused by transmission within the UK, with two
patients having arrived in the UK from Asia in the
previous five years, and with no known epidemiologi-
cal link within the UK. The remaining three clusters
were of two cases each, one likely to be caused by
household transmission (LAM9).
DISCUSSION
The proportion of cases of tuberculosis resistant to
isoniazid has increased during 1998-2005 in England,
Wales, and Northern Ireland. This rise reflects the
increasing proportion of patients with tuberculosis who
are not born in the UK and who are from certain ethnic
minority groups, as well as inadequate control of
transmission in London. Levels of multidrug resistance
and rifampicin resistance also showed a small increase.
Levels of multidrug resistance in the UK are similar to
those in other Western European countries.20
Strengths and limitations
In London, the prevalence of tuberculosis is high
among homeless people and problem drug users, who
are often infectious, difficult to treat, and have drug
resistant disease.21 Such cases might be disproportio-
nately under-represented in surveillance data, which
might lead to an underestimate of the proportion of,
and increase in, drug resistance in London. Another
limitation of this study is the inability to adjust for the
effects of some risk factors, such as coinfection with
HIV or deprivation, on the observed trends in drug
resistance.As in other observational studies, we cannot
exclude the effect of residual confounding related to
factors in themodel. Although the numbers of resistant
cases were not large, potentially obscuring significant
effects, the consistency of the results strengthens the
conclusions. Stratification of the analysis for isoniazid
resistance also affects statistical power but was deemed
necessary because of a priori knowledge of the
isoniazid resistant outbreak in north London.2
We needed to match two databases to combine data
on drug susceptibility with demographic and clinical
data. As the variables used for record linkage might be
incomplete or incorrect in either database, we cannot
exclude some inaccuratematches.Asweused the same
matching algorithm over the time period studied,
however, it is unlikely that such errors would affect the
trends observed. Data on drug resistance were not
available for 46% of reported cases (most of these cases
were not culture confirmed), allowing scope for bias.
Nevertheless, this is attenuated by the fact that this
proportion remained stable over the study period and
that excluded patients were similar in terms of age,
Table 3 | Oddsratios(95%confidenceinterval)forisoniazidresistanttuberculosisinEngland,Wales,andNorthernIreland,1998-2005,stratifiedbyregionofreporting
London Outside London
No
tested
%
resistant Univariable model Multivariablemodel†
No
tested
%
resistant Univariable model Multivariable model†
Age (linear) 11 848 8.5 0.98 (0.98 to 0.99)*** 0.99 (0.98 to 0.99)*** 16 633 3.0 0.98 (0.98 to 0.98)*** 0.98 (0.98 to 0.99)***
Sex:
Female 5056 8.1 0.91 (0.80 to 1.04) 0.92 (0.79 to 1.08) 7227 2.9 0.94 (0.82 to 1.08) 0.81 (0.69 to 0.96)*
Male 6783 8.8 Reference 9381 3.1 Reference
Born in UK:
No 8822 7.9 0.69 (0.59 to 0.82)*** 0.76 (0.60 to 0.95)* 8700 3.2 1.92 (1.63 to 2.25)*** 1.49 (1.16 to 1.92)*
Yes 1806 11.1 Reference 6229 2.7 Reference
Ethnic group‡:
White 1747 7.7 Reference 5794 2.3 Reference
Black Caribbean 470 21.5 3.27 (2.47 to 4.33) 2.93 (2.11 to 4.09) 300 2.1 1.82 (1.08 to 3.08) 1.35 (0.77 to 2.36)
Black African 3877 8.7 1.14 (0.92 to 1.40) 1.08 (0.80 to 1.45) 2090 2.1 2.11 (1.67 to 2.66) 0.99 (0.68 to 1.43)
Black other 174 10.9 1.46 (0.88 to 2.43) 1.38 (0.75 to 2.55) 67 1.2 1.51 (0.47 to 4.87) 0.99 (0.30 to 3.28)
Indian, Pakistani, Bangladeshi 3606 6.8 0.87 (0.70 to 1.08) 0.89 (0.66 to 1.19) 6357 4.0 2.14 (1.78 to 2.57) 1.26 (0.94 to 1.69)
Chinese 174 9.8 1.29 (0.76 to 2.20) 1.41 (0.75 to 2.64) 274 5.1 2.96 (1.88 to 4.66) 1.71 (0.99 to 2.95)
Other 1464 8.4 1.10 (0.85 to 1.41) 1.04 (0.74 to 1.46) 863 3.2 3.07 (2.32 to 4.07) 1.65 (1.11 to 2.44)
Year (linear) 11 851 8.5 1.05 (1.02 to 1.08)** 1.04 (1.00 to 1.07)* 16 634 3.0 1.04 (1.01 to 1.07)* 1.01 (0.98 to 1.05)
Previous diagnosis:
Yes 655 10.2 1.23 (0.95 to 1.60) 1.35 (1.02 to 1.78)* 1234 3.2 1.44 (1.14 to 1.82)** 1.80 (1.40 to 2.32)***
No 8504 8.5 Reference 12 278 0.7 Reference
Site of disease:
Pulmonary 7556 9.0 1.18 (1.03 to 1.36)* 1.06 (0.89 to 1.25) 11 441 2.8 0.73 (0.63 to 0.84)*** 0.82 (0.69 to 0.98)
Extrapulmonary 4247 7.7 Reference 5097 3.4 Reference
*P<0.05, **P<0.01, ***P<0.001.
†Adjusted for age, sex, place of birth, ethnic group, previous diagnosis, and site of disease.
‡Overall significance: P<0.001 for univariable and multivariable models for London and univariables model for outside London; P<0.05 for multivariable models outside London.
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place of birth, and ethnic group, which were associated
with both drug resistance and year of reporting.
Explanations for increases in drug resistance
The increase in isoniazid resistance outside London
was related to increasing numbers of patients born
outside theUKand also to changes in ethnic group and
age. We found a strong association between drug
resistance and the Chinese ethnic group. Anti-
tuberculosis drug resistance is particularly high and
increasing in some provinces of China and in countries
of the former Soviet Union.22 23 Additional analyses,
however, showed that few patients with drug resistant
tuberculosis came from these regions (1.3% and 0.5%
with any first line drug resistance, respectively) nor
fromtheEasternEuropeancountries thathave recently
joined the European Union (0.4%). The increase in
isoniazid resistance is probably related to increasing
numbers of patients with drug resistant tuberculosis
from sub-Saharan Africa and the Indian subcontinent.
The increase in cases from these parts of the world
reflects, at least in part, a general change in the UK
population resulting from ongoing migration.
In London, the trend cannot be explained by
changing demographic characteristics of patients and
is probably related to a major outbreak of isoniazid
monoresistant tuberculosis, first noted in 1999.1 2
Additional analysis of the effect of the outbreak on
the trend in London confirmed this relation (including
membership of the outbreak into the multivariable
model resulted in a non-significant odds ratio for year
of 1.01, 0.97 to 1.05). The same analysis also suggested
that this outbreak, which includes mainly white and
black Caribbean people born in the UK, accounts for
thehigher riskof isoniazid resistance inpatients born in
the UK and living in London. The outbreak is
associated with imprisonment and drug misuse. More
than 300 cases have been identified to date as part of
this outbreak,mainly in northLondon.Theoutbreak is
still continuing, suggesting that control measures are
insufficient. Clinicians within London, including gen-
eral practitioners, should be more aware in UK born
people presenting with symptoms consistent with
tuberculosis and refer them promptly. When appro-
priate, clinical services should also provide additional
support to ensure that patients complete treatment.
Rifampicin resistance and multidrug resistance also
increased as a result of changes in demographic
characteristics and as well as clinical characteristics of
patients. Nevertheless, the overall increase was small:
rifampicin resistance rose from1.0% in 1998 to 1.2% in
2005 and multidrug resistance from 0.8% to 0.9%.
Table 4 | Odds ratios (95%confidence interval) for rifampicin andmultidrug resistant tuberculosis in England,Wales, and Northern Ireland, 1998-2005
No tested
Rifampicin resistance Multidrug resistance
% resistant Univariable model Multivariable model† % resistant Univariable models Multivariable model†
Age (linear) 28 481 1.2 0.98 (0.97 to 0.99)*** 0.98 (0.97 to 0.99)*** 0.9 0.97 (0.96 to 0.98)*** 0.98 (0.97 to 0.99)***
Sex:
Female 12 283 1.2 0.92 (0.74 to 1.14) 0.83 (0.64 to 1.08) 0.9 0.96 (0.75 to 1.24) 0.80 (0.59 to 1.08)
Male 16 164 1.3 Reference 0.9 Reference
Born in UK:
No 17 522 1.4 1.93 (1.46 to 2.56)*** 1.88 (1.24 to 2.86)** 1.1 2.17 (1.54 to 3.05)*** 1.62 (0.99 to 2.66)‡
Yes 8035 0.7 Reference 0.5 Reference
Ethnic group§:
White 7541 0.7 Reference 0.4 Reference
Black Caribbean 770 9.1 1.82 (0.93 to 3.60) 1.28 (0.59 to 2.79) 0.5 1.40 (0.49 to 4.01) 1.01 (0.30 to 3.43)
Black African 5967 1.7 2.36 (1.69 to 3.30) 0.98 (0.59 to 1.64) 1.3 3.60 (2.34 to 5.55) 1.77 (0.92 to 3.41)
Black other 241 2.5 3.54 (1.51 to 8.31) 1.87 (0.69 to 5.06) 1.7 4.53 (1.58 to 13.01) 2.44 (0.68 to 8.81)
Indian, Pakistani, Bangladeshi 9963 1.2 1.69 (1.22 to 2.33) 0.94 (0.59 to 1.50) 1.0 2.64 (1.73 to 4.02) 1.63 (0.91 to 2.95)
Chinese 448 1.3 1.88 (0.81 to 4.40) 0.83 (0.28 to 2.45) 1.1 3.03 (1.16 to 7.88) 1.77 (0.56 to 5.54)
Other 2327 1.7 2.42 (1.61 to 3.66) 0.97 (0.54 to 1.75) 1.2 3.15 (1.85 to 5.36) 1.32 (0.62 to 2.84)
Year (linear) 28 485 1.2 1.06 (1.01 to 1.11)* 1.03 (0.98 to 1.09) 0.9 1.06 (1.00 to 1.12)* 1.01 (0.95 to 1.08)
Region of reporting:
London 11 851 1.5 1.50 (1.22 to 1.86)*** 0.81 (0.62 to 1.05) 1.0 1.25 (0.97 to 1.60)‡ 1.04 (0.76 to 1.42)
Outside London 16 634 1.0 Reference 0.8
Previous diagnosis:
Yes 1889 3.5 3.82 (2.89 to 5.06)*** 4.72 (3.50 to 6.35)*** 2.8 4.29 (3.11 to 5.90)*** 5.44 (3.88 to 7.63)***
No 20 782 1.0 Reference 0.7 Reference
Site of disease:
Pulmonary 18 997 1.3 1.35 (1.06 to 1.72)* 1.48 (1.10 to 1.98)* 1.0 1.26 (0.95 to 1.66) 1.40 (1.00 to 1.96)‡
Extrapulmonary 9344 1.0 Reference 0.8 Reference
*P<0.05, **P<0.01, ***P<0.001.
†Adjusted for age, sex, place of birth, region of reporting, ethnic group, previous diagnosis and site of disease.
‡Borderline significance (P<0.1).
§Overall significance: P<0.001 for univariable models for rifampicin and multidrug resistance.
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Furthermore the reported level of multidrug resistance
in 1993-9 was higher (1.2%).4 Although this change
might not be substantial, further measures are war-
ranted to prevent a sustained increase.
Transmission and management of multidrug resistant
tuberculosis
The proportion ofmultidrug resistant cases resistant to
second and third line drugs was also low, with only one
case of extensively drug resistant tuberculosis identi-
fied. The low proportion could suggest that such
patients are being managed effectively, preventing the
emergence of further resistance. Because of the small
numbers of cases tested, however, we could not assess
whether levels have increased over time.
Most cases ofmultidrug resistant tuberculosis are not
causedbyrecent transmission in theUK.Among the66
patients with strain typing information, 19 were part of
six clusters of identical MIRU-VNTR patterns. After
allowance for one potential source case in each cluster,
the estimated proportion of cases clustered was 20%,
suggesting that transmission of multidrug resistant
tuberculosis within the UK is limited. Cases that arise
de novo, rather than as a result of recent transmission,
suggest that failures in management of patients in the
UK are contributing to the occurrence of multidrug
resistance.
Conclusions
The increase in isoniazid resistance underlines the
importance of using the recommended four drug
course in the initial treatment phase for patients with
tuberculosis10 and of implementing measures to con-
trol the isoniazid resistant outbreak in London. The
small increases in multidrug resistance and rifampicin
resistance suggest a potential trend, which needs to be
monitored. Increased awareness, early case detection,
rapid drug susceptibility testing, completion of treat-
ment, continuous surveillance, and a contribution to
control of tuberculosis in high incidence countries are
needed to halt the observed trends.
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